Precision in Psychiatry – Leveraging Personalized Medicine

​Join us for a compelling exploration into the future of mental health care, where cutting-edge science converges with patient-centric innovation. This session, led by Dr. Nick Sireau, CEO and Co-founder of Serenatis Bio, and Lina Gaydarova, Investment Manager at Novaterra Ventures, delves into the transformative potential of precision psychiatry.

​Nick brings a unique perspective, combining his personal journey as a mental health advocate with his leadership in developing novel treatments for obsessive-compulsive disorder (OCD) through Serenatis Bio and Orchard OCD. His experience underscores the importance of integrating patient experiences into therapeutic development. 

​Lina offers insights from the investment landscape, highlighting how Novaterra Ventures supports pioneering ventures at the intersection of neuroscience and personalised medicine. Her expertise sheds light on the critical role of strategic funding in advancing innovative mental health solutions. 

​Together, they will discuss how leveraging genetic, neurobiological, EEG and digital biomarkers can lead to more effective, individualized treatments for mental health disorders. Attendees will gain a deeper understanding of the challenges and opportunities in implementing precision medicine approaches in psychiatry, and the collaborative efforts required to bring these innovations from bench to bedside.

​Whether you’re a founder, researcher, investor, or advocate, this session offers valuable perspectives on the evolving landscape of mental health treatment and the promise of personalised care.